Authors
- . Nahid Eskandari 1
- . Omid Mirmosayyeb 2
- . Gazaleh Bordbari 2
- . Reza Bastan 3
- . Zahra Yousefi 2
- . Alireza Andalib 2
1 Department of Immunology, Isfahan University of Medical Sciences, Isfahan, Iran Applied Physiology Research Center, Isfahan University of Medical Sciences, Isfahan, Iran
2 Department of Immunology, Isfahan University of Medical Sciences, Isfahan, Iran
3 Department of Human Vaccines, Razi Serum and Vaccine Research Institute, Karaj, Alborz, Iran
Abstract
Cyclic nucleotide phosphodiesterases (PDEs) are known as a super‑family of enzymes
which catalyze the metabolism of the intracellular cyclic nucleotides, cyclic‑3’,5’‑adenosine
monophosphate (cAMP), and cyclic‑3’,5’‑guanosine monophosphate that are expressed in
a variety of cell types that can exert various functions based on their cells distribution. The
PDE4 family has been the focus of vast research efforts over recent years because this family
is considered as a prime target for therapeutic intervention in a number of inflammatory
diseases such as asthma, chronic obstructive pulmonary disease, and rheumatoid arthritis,
and it should be used and researched by pharmacists. This is because the major isoform of
PDE that regulates inflammatory cell activity is the cAMP‑specific PDE, PDE4. This review
discusses the relationship between PDE4 and its inhibitor drugs based on structures, cells
distribution, and pharmacological properties of PDE4 which can be informative for all
pharmacy specialists.
Keywords
- GuoL, LuoL, JuR, ChenC, ZhuL, LiJ, etal. Carboxyamidotriazole:
A novel inhibitor of both cAMP‑phosphodiesterases and
cGMP‑phosphodiesterases. Eur J Pharmacol 2015;746:14‑21.
2. Rickles RJ, Pierce LT, Giordano TP 3rd, Tam WF, McMillin DW,
Delmore J, et al. Adenosine A2A receptor agonists and
PDE inhibitors: A synergistic multitarget mechanism
discovered through systematic combination screening in B‑cell
malignancies. Blood 2010;116:593‑602.
3. Ahmad F, Murata T, Shimizu K, Degerman E, Maurice D,
Manganiello V. Cyclic nucleotide phosphodiesterases:
Important signaling modulators and therapeutic targets. Oral
Dis 2015;21:e25‑50.
4. Chen X, Zhao X, Xiong Y, Liu J, Zhan CG. Fundamental
reaction pathway and free energy profile for hydrolysis
of intracellular second messenger adenosine 3’,5’‑cyclic
monophosphate (cAMP) catalyzed by phosphodiesterase‑4.
J Phys Chem B 2011;115:12208‑19.
5. Blaha M, Nemcova L, Prochazka R. Cyclic guanosine
monophosphate does not inhibit gonadotropin‑induced
activation of mitogen‑activated protein kinase 3/1 in pig
cumulus‑oocyte complexes. Reprod Biol Endocrinol 2015;13:1.
6. Madhani M, Scotland RS, MacAllister RJ, Hobbs AJ. Vascular
natriuretic peptide receptor‑linked particulate guanylate
cyclases are modulated by nitric oxide‑cyclic GMP signalling.
Br J Pharmacol 2003;139:1289‑96.
7. Lugnier C. Cyclic nucleotide phosphodiesterase (PDE)
superfamily: A new target for the development of specific
therapeutic agents. Pharmacol Ther 2006;109:366‑98.
8. Demirbas D, Wyman AR, Shimizu‑Albergine M, Cakici O,
Beavo JA, Hoffman CS. A yeast‑based chemical screen
identifies a PDE inhibitor that elevates steroidogenesis in
mouse Leydig cells via PDE8 and PDE4 inhibition. PLoS One
2013;8:e71279.
9. Wunder F, Tersteegen A, Rebmann A, Erb C, Fahrig T,
Hendrix M. Characterization of the first potent and selective
PDE9 inhibitor using a cGMP reporter cell line. Mol Pharmacol
2005;68:1775‑81.
10. Biswas KH, Sopory S, Visweswariah SS. The GAF domain of
the cGMP‑binding, cGMP‑specific phosphodiesterase (PDE5)
is a sensor and a sink for cGMP. Biochemistry 2008;47:3534‑43.
11. Han P, Zhu X, Michaeli T. Alternative splicing of the
high affinity cAMP‑specific phosphodiesterase (PDE7A)
mRNA in human skeletal muscle and heart. J Biol Chem
1997;272:16152‑7.
12. Lau JK, Li XB, Cheng YK. Asubstrate selectivity and inhibitor
design lesson from the PDE10‑cAMP crystal structure: A
computational study. J Phys Chem B 2010;114:5154‑60.
13. Fawcett L, Baxendale R, Stacey P, McGrouther C, Harrow I,
Soderling S, et al. Molecular cloning and characterization of
a distinct human phosphodiesterase gene family: PDE11A.
Proc Natl Acad Sci U S A 2000;97:3702‑7.
14. Yuasa K, Kotera J, Fujishige K, Michibata H, Sasaki T, Omori K.
Isolation and characterization of two novel phosphodiesterase
PDE11A variants showing unique structure and tissue‑specific
expression. J Biol Chem 2000;275:31469‑79.
15. Beavo JA, Reifsnyder DH. Primary sequence of cyclic
nucleotide phosphodiesterase isozymes and the design of
selective inhibitors. Trends Pharmacol Sci 1990;11:150‑5.
16. Goldstein I, Lue TF, Padma‑Nathan H, Rosen RC, Steers WD,
Wicker PA. Oral sildenafil in the treatment of erectile
dysfunction. Sildenafil Study Group. N Engl J Med
1998;338:1397‑404.
17. Souness JE, Aldous D, Sargent C. Immunosuppressive and
anti‑inflammatory effects of cyclic AMP phosphodiesterase
(PDE) type 4 inhibitors. Immunopharmacology 2000;47:127‑62.
18. Lipworth BJ. Phosphodiesterase‑4 inhibitors for asthma and
chronic obstructive pulmonary disease. Lancet 2005;365:167‑75.
19. Franciosi LG, Diamant Z, Banner KH, Zuiker R, Morelli N,
Kamerling IM, et al. Efficacy and safety of RPL554, a dual PDE3
and PDE4 inhibitor, in healthy volunteers and in patients with
asthma or chronic obstructive pulmonary disease: Findings
from four clinical trials. Lancet Respir Med 2013;1:714‑27.
20. BinMahfouz H, Borthakur B, Yan D, George T, Giembycz MA,
Newton R. Superiority of combined phosphodiesterase PDE3/
PDE4 inhibition over PDE4 inhibition alone on glucocorticoid‑
and long‑acting ß2‑adrenoceptor agonist‑induced gene
expression in human airway epithelial cells. Mol Pharmacol
2015;87:64‑76.
21. SuvarnaNU, O’DonnellJM. Hydrolysis of N‑methyl‑D‑aspartate
receptor‑stimulated cAMP and cGMP by PDE4 and PDE2
phosphodiesterases in primary neuronal cultures of rat
cerebral cortex and hippocampus. J Pharmacol Exp Ther
2002;302:249‑56.
22. Akaike N, Furukawa K, Kogure K. Rolipram enhances
the development of voltage‑dependent Ca2+current and
serotonin‑induced current in rat pheochromocytoma cells.
Brain Res 1993;620:58‑63.
23. Bao Z, Feng Y, Wang H, Zhang C, Sun L, Yan Z, et al. Integrated
analysis using methylation and gene expression microarrays
reveals PDE4C as a prognostic biomarker in human glioma.
Oncol Rep 2014;32:250‑60.
24. Horton YM, Sullivan M, Houslay MD. Molecular cloning of
a novel splice variant of human type IVA (PDE‑IVA) cyclic
AMP phosphodiesterase and localization of the gene to
the p13.2‑q12 region of human chromosome 19 [corrected].
Biochem J 1995;308 (Pt 2):683‑91.
25. Engels P, Sullivan M, Müller T, Lübbert H. Molecular
cloning and functional expression in yeast of a human
cAMP‑specific phosphodiesterase subtype (PDE IV‑C). FEBS
Lett 1995;358:305‑10. - 26. Houslay MD, Schafer P, Zhang KY. Keynote review:
Phosphodiesterase‑4 as a therapeutic target. Drug Discov
Today 2005;10:1503‑19.
27. OwensRJ, Catterall C, Batty D, Jappy J, RussellA, Smith B, et al.
Human phosphodiesterase 4A: Characterization of full‑length
and truncated enzymes expressed in COS cells. Biochem J
1997;326 (Pt 1):53‑60.
28. Lario PI, Bobechko B, Bateman K, Kelly J, VrielinkA, Huang Z.
Purification and characterization of the human PDE4A
catalytic domain (PDE4A330‑723) expressed in Sf9 cells. Arch
Biochem Biophys 2001;394:54‑60.
29. Richter W, Conti M. The oligomerization state determines
regulatory properties and inhibitor sensitivity of
type 4 cAMP‑specific phosphodiesterases. J Biol Chem
2004;279:30338‑48.
30. Peters M, Bletsch M, Stanley J, Wheeler D, Scott R, Tully T. The
PDE4 inhibitor HT‑0712 improves hippocampus‑dependent
memory in aged mice. Neuropsychopharmacology
2014;39:2938‑48.
31. Beard MB, Huston E, Campbell L, Gall I, McPhee I, Yarwood S,
et al. In addition to the SH3 binding region, multiple
regions within the N‑terminal noncatalytic portion of the
cAMP‑specific phosphodiesterase, PDE4A5, contribute to its
intracellular targeting. Cell Signal 2002;14:453‑65.
32. KimJS, BaileyMJ, HoAK, Møller M, GaildratP, KleinDC. Daily
rhythm in pineal phosphodiesterase (PDE) activity reflects
adrenergic/3’,5’‑cyclic adenosine 5’‑monophosphate induction
of the PDE4B2 variant. Endocrinology 2007;148:1475‑85.
33. BolgerGB, DunlopAJ, MengD, DayJP, KlussmannE, BaillieGS,
et al. Dimerization of cAMP phosphodiesterase‑4 (PDE4) in
living cells requires interfaces located in both the UCR1 and
catalytic unit domains. Cell Signal 2015;27:756‑69.
34. El Bawab S, Macovschi O, Sette C, Conti M, Lagarde M,
Nemoz G, et al. Selective stimulation of a cAMP‑specific
phosphodiesterase (PDE4A5) isoform by phosphatidic acid
molecular species endogenously formed in rat thymocytes.
Eur J Biochem 1997;247:1151‑7.
35. Swinnen JV, D’Souza B, Conti M, Ascoli M. Attenuation of
cAMP‑mediated responses in MA‑10 Leydig tumor cells by
genetic manipulation of a cAMP‑phosphodiesterase. J Biol
Chem 1991;266:14383‑9.
36. Marquette A, André J, Bagot M, Bensussan A, Dumaz N.
ERK and PDE4 cooperate to induce RAF isoform switching
in melanoma. Nat Struct Mol Biol 2011;18:584‑91.
37. Boomkamp SD, McGrath MA, Houslay MD, Barnett SC. Epac
and the high affinity rolipram binding conformer of PDE4
modulate neurite outgrowth and myelination using an in vitro
spinal cord injury model. Br J Pharmacol 2014;171:2385‑98.
38. Eskandari N, Bastan R, Ahmadi M, Peachell PT. Evaluation
of the correlation and reproducibility between histamine,
IL‑4, and IL‑13 release from human basophils. Iran J Allergy
Asthma Immunol 2014;13:190‑7.
39. Weston MC, Anderson N, Peachell PT. Effects of
phosphodiesterase inhibitors on human lung mast cell and
basophil function. Br J Pharmacol 1997;121:287‑95.
40. Zhao Y, Zhang HT, O’Donnell JM. Inhibitor binding to type 4
phosphodiesterase (PDE4) assessed using [3H] piclamilast
and [3H] rolipram. J Pharmacol Exp Ther 2003;305:565‑72.
41. Lagente V, Martin‑Chouly C, Boichot E, MartinsMA, Silva PM.
Selective PDE4 inhibitors as potent anti‑inflammatory drugs
for the treatment of airway diseases. Mem Inst Oswaldo Cruz
2005;100 Suppl 1:131‑6.
42. Beghè B, Rabe KF, Fabbri LM. Phosphodiesterase‑4 inhibitor
therapy for lung diseases. Am J Respir Crit Care Med
2013;188:271‑8.
43. De Savi C, Cox RJ, Warner DJ, Cook AR, Dickinson MR,
McDonough A, et al. Efficacious inhaled PDE4 inhibitors
with low emetic potential and long duration of action for the
treatment of COPD. J Med Chem 2014;57:4661‑76.
44. Patel BS, Prabhala P, Oliver BG, Ammit AJ. Inhibitors of
Phosphodiesterase 4, but Not Phosphodiesterase 3, Increase
ß2‑Agonist‑Induced Expression of Antiinflammatory
Mitogen‑Activated Protein Kinase Phosphatase 1 in Airway
Smooth Muscle Cells. Am J Respir Cell Mol Biol 2015;52:634‑40.
45. Eskandari N, Bastan R, Peachell PT. Regulation of human
skin mast cell histamine release by PDE inhibitors. Allergol
Immunopathol (Madr) 2015;43:37‑41.
46. Giembycz MA, Maurice DH. Cyclic nucleotide‑based
therapeutics for chronic obstructive pulmonary disease. Curr
Opin Pharmacol 2014;16:89‑107.
47. GiembyczMA, NewtonR. How phosphodiesterase 4 inhibitors
work in patients with chronic obstructive pulmonary disease
of the severe, bronchitic, frequent exacerbator phenotype. Clin
Chest Med 2014;35:203‑17.
48. Shan WJ, Huang L, Zhou Q, Jiang HL, Luo ZH, Lai KF,
et al. Dual ß2‑adrenoceptor agonists‑PDE4 inhibitors for
the treatment of asthma and COPD. Bioorg Med Chem Lett
2012;22:1523‑6.
49. Ochiai K, Takita S, Eiraku T, Kojima A, Iwase K, Kishi T, et al.
Phosphodiesterase inhibitors. Part 3: Design, synthesis and
structure‑activity relationships of dual PDE3/4‑inhibitory
fused bicyclic heteroaromatic‑dihydropyridazinones with
anti‑inflammatory and bronchodilatory activity. Bioorg Med
Chem 2012;20:1644‑58.
50. Eskandari N, Wickramasinghe T, Peachell PT. Effects
of phosphodiesterase inhibitors on interleukin‑4 and
interleukin‑13 generation from human basophils. Br J
Pharmacol 2004;142:1265‑72.
51. Brunnée T, Engelstätter R, Steinijans VW, Kunkel G.
Bronchodilatory effect of inhaled zardaverine, a
phosphodiesterase III and IV inhibitor, in patients with
asthma. Eur Respir J 1992;5:982‑5.
52. Mokry J, Joskova M, Mokra D, Christensen I, Nosalova G.
Effects of selective inhibition of PDE4 and PDE7 on airway
reactivity and cough in healthy and ovalbumin‑sensitized
guinea pigs. Adv Exp Med Biol 2013;756:57‑64.
)